DDInter948 DDInter714
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
Fedratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Fedratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Fedratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pralsetinib
Fedratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abametapir
Fedratinib {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Fedratinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Fedratinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Fedratinib may lead to a major life threatening interaction when taken with Tamoxifen
Fedratinib may lead to a major life threatening interaction when taken with Lurbinectedin